RT Journal Article
SR Electronic
T1 793 Combined administration of the dual A<sub>2a</sub>R/A<sub>2b</sub>R antagonist etrumadenant with a reduced chemotherapy regimen leads to enhanced tumor efficacy and survival
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A890
OP A890
DO 10.1136/jitc-2023-SITC2023.0793
VO 11
IS Suppl 1
A1 Marubayashi, Sachie
A1 Piovesan, Dana
A1 Soriano, Ferdie
A1 Barajas, Gonzalo
A1 Flores, Ruben
A1 Kline, Janine
A1 Walters, Matthew J
A1 DiRenzo, Daniel
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A890.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.